Protalix (PLX) Director Elze Christian Receives Stock Option & RSU Awards

What Happened

• Elze Christian, a director of Protalix BioTherapeutics (PLX), received award grants on 2026-09-03: a derivative grant covering 17,000 shares (stock options or option-like derivatives) and 8,500 restricted stock units (RSUs). Both awards show an acquisition price of $0.00 in the filing (typical for grants/awards) and were reported on Form 4 filed 2026-09-04. These are awards/compensation grants rather than open-market purchases or sales.

Key Details

• Transaction date: September 3, 2026; Form 4 filed September 4, 2026 (no late filing indicated).
• Reported amounts: 17,000 derivative shares (options/option-like award) and 8,500 RSUs; acquisition price $0.00 per share as reported.
• Vesting: Both the option-based award and the RSUs vest in 12 equal quarterly installments commencing on the grant date (i.e., quarterly over ~3 years) (see footnotes F1 and F4).
• RSU mechanics: Each RSU represents the right to receive one share of common stock upon vesting (footnote F3).
• Existing holdings: Filing notes this grant does not include previously held options to purchase 15,000 shares at $1.64 expiring Sept 3, 2035 (footnote F2).
• Shares owned after transaction: Not disclosed in the provided excerpt.

Context

• RSUs convert to company shares only as they vest; no immediate shares or sale proceeds occur at grant. Option/derivative grants give the right to acquire shares under plan terms; the filing does not list an exercise price for the newly reported derivative grant. Awards are commonly compensation for service and do not by themselves indicate a buy/sell market action.